The following is a list of the top 100 prescribed medicines by U.S. National Sales in Q2 2012. Figures include sales through both retail and hospital channels, listed by drug name and sales value in U.S. dollars.
| Rank |
Drug |
Sales ($000) |
|
|
1 ( 1) |
Nexium
AstraZeneca Pharmaceuticals |
1,380,413 |
-1.12% |
Stats |
| 2 (1) |
Abilify
Otsuka Pharmaceutical Co. |
1,379,149 |
2.91% |
Stats |
| 3 (1) |
Singulair
Merck & Co., Inc. |
1,287,806 |
4.01% |
Stats |
| 4 (2) |
Advair Diskus
GlaxoSmithKline |
1,124,985 |
-1.25% |
Stats |
| 5 (2) |
Crestor
AstraZeneca Pharmaceuticals |
1,124,702 |
0.61% |
Stats |
| 6 (2) |
Cymbalta
Eli Lilly and Company |
1,057,821 |
2.77% |
Stats |
| 7 (3) |
Humira
Abbott Laboratories |
1,015,639 |
9.43% |
Stats |
| 8 (4) |
Enbrel
Amgen Inc. |
948,119 |
6.51% |
Stats |
9 ( 8) |
Plavix
Bristol-Myers Squibb Company |
934,731 |
-42.33% |
Stats |
| 10 (1) |
Remicade
Centocor Ortho Biotech, Inc |
933,255 |
3.76% |
Stats |
| 11 (2) |
Neulasta
Amgen Inc. |
842,628 |
-0.86% |
Stats |
| 12 (3) |
Rituxan
Genentech, Inc |
819,418 |
8.26% |
Stats |
| 13 (3) |
Copaxone
Teva Pharmaceuticals |
798,336 |
6.65% |
Stats |
| 14 (5) |
atorvastatin
Generic |
784,007 |
-17.68% |
Stats |
| 15 (3) |
OxyContin
|
683,693 |
3.14% |
Stats |
| 16 (1) |
Atripla
Gilead Sciences, Inc. |
683,070 |
-1.70% |
Stats |
| 17 (2) |
Spiriva
Boehringer Ingelheim Pharmaceuticals, Inc |
661,211 |
0.21% |
Stats |
| 18 (2) |
Avastin
Genentech, Inc |
647,721 |
2.46% |
Stats |
| 19 (3) |
Januvia
Merck & Co., Inc. |
605,840 |
3.81% |
Stats |
| 20 (6) |
Lipitor
Pfizer Inc |
579,297 |
-31.09% |
Stats |
| 21 |
Actos
Takeda Pharmaceuticals North America, Inc |
574,553 |
-8.94% |
Stats |
| 22 (5) |
Epogen
Amgen Inc. |
554,848 |
13.33% |
Stats |
| 23 |
Truvada
Gilead Sciences, Inc. |
542,835 |
-0.60% |
Stats |
| 24 |
Lantus
Sanofi-Aventis |
529,983 |
1.81% |
Stats |
| 25 |
Diovan
Novartis Corporation |
490,315 |
-3.79% |
Stats |
| 26 (3) |
Lantus Solostar
Sanofi-Aventis |
481,022 |
7.28% |
Stats |
| 27 (3) |
enoxaparin
Generic |
461,889 |
4.44% |
Stats |
| 28 |
Lyrica
Pfizer Inc |
454,575 |
-0.78% |
Stats |
| 29 (2) |
Eloxatin
Sanofi-Aventis |
454,567 |
5.24% |
Stats |
| 30 (3) |
Herceptin
Genentech, Inc |
454,063 |
6.67% |
Stats |
| 31 (1) |
Celebrex
Pfizer Inc |
437,140 |
1.43% |
Stats |
| 32 (46) |
escitalopram
Generic |
416,370 |
98.11% |
Stats |
| 33 (6) |
Avonex
Biogen Idec |
414,293 |
6.61% |
Stats |
| 34 (4) |
Gleevec
Novartis Corporation |
411,455 |
5.21% |
Stats |
| 35 (2) |
Namenda
Forest Pharmaceuticals, Inc |
407,937 |
4.16% |
Stats |
| 36 (2) |
Diovan HCT
Novartis Corporation |
402,445 |
-3.14% |
Stats |
| 37 (2) |
Lucentis
Genentech, Inc |
389,387 |
-4.92% |
Stats |
| 38 (2) |
Vyvanse
Shire US Inc |
375,563 |
-3.00% |
Stats |
| 39 (4) |
One Touch Ultra
|
362,111 |
-1.14% |
Stats |
| 40 (2) |
Incivek
Vertex Pharmaceuticals |
360,525 |
-2.91% |
Stats |
| 41 (4) |
methylphenidate
Generic |
346,906 |
2.88% |
Stats |
| 42 (2) |
Suboxone
Reckitt Benckiser Pharmaceuticals Inc. |
342,816 |
1.17% |
Stats |
| 43 (3) |
Zetia
Merck & Co., Inc. |
336,926 |
2.52% |
Stats |
| 44 (3) |
AndroGel
Abbott Laboratories |
326,838 |
4.81% |
Stats |
| 45 (4) |
Lidoderm
Endo Pharmaceuticals |
305,673 |
1.43% |
Stats |
| 46 (5) |
Symbicort
AstraZeneca Pharmaceuticals |
294,803 |
1.42% |
Stats |
| 47 (11) |
Procrit
Janssen Pharmaceuticals, Inc |
292,501 |
10.72% |
Stats |
| 48 (2) |
TriCor
Abbott Laboratories |
291,015 |
-2.62% |
Stats |
| 49 (13) |
Rebif
|
283,208 |
9.73% |
Stats |
| 50 (9) |
Alimta
Eli Lilly and Company |
280,190 |
6.53% |
Stats |
| 51 (4) |
amphetamine/dextroamphetamine
Generic |
275,171 |
-0.10% |
Stats |
| 52 (4) |
Nasonex
Merck & Co., Inc. |
272,661 |
-0.76% |
Stats |
| 53 (1) |
Combivent
Boehringer Ingelheim Pharmaceuticals, Inc |
270,254 |
-5.34% |
Stats |
| 54 (3) |
Novolog
Novo Nordisk Inc. |
270,047 |
1.41% |
Stats |
| 55 (1) |
Seroquel XR
AstraZeneca Pharmaceuticals |
268,071 |
-5.08% |
Stats |
| 56 (4) |
Viagra
Pfizer Inc |
256,066 |
-1.77% |
Stats |
| 57 (11) |
Levemir
Novo Nordisk Inc. |
255,344 |
6.58% |
Stats |
| 58 (15) |
metoprolol
Generic |
251,955 |
8.89% |
Stats |
| 59 (5) |
Niaspan
Abbott Laboratories |
251,071 |
-1.69% |
Stats |
| 60 (7) |
Lovaza
GlaxoSmithKline |
244,963 |
2.13% |
Stats |
| 61 (5) |
Flovent HFA
GlaxoSmithKline |
243,193 |
0.68% |
Stats |
| 62 (8) |
Neupogen
Amgen Inc. |
242,012 |
1.50% |
Stats |
| 63 (11) |
NovoLog FlexPen
Novo Nordisk Inc. |
241,972 |
6.49% |
Stats |
| 64 (11) |
ProAir HFA
Teva Pharmaceuticals |
238,874 |
-16.08% |
Stats |
| 65 (6) |
Reyataz
Bristol-Myers Squibb Company |
233,330 |
-2.02% |
Stats |
| 66 (1) |
Humalog
Eli Lilly and Company |
232,698 |
-4.86% |
Stats |
67 ( ) |
modafinil
Generic |
230,253 |
 |
Stats |
| 68 (9) |
Isentress
Merck & Co., Inc. |
227,514 |
7.56% |
Stats |
| 69 (3) |
Aranesp
Amgen Inc. |
223,161 |
-3.66% |
Stats |
| 70 (6) |
Janumet
Merck & Co., Inc. |
217,003 |
2.07% |
Stats |
| 71 (4) |
Vytorin
Merck & Co., Inc. |
215,274 |
-1.35% |
Stats |
| 72 (3) |
Adderall XR
Shire US Inc |
214,713 |
-10.20% |
Stats |
| 73 (6) |
Cialis
Eli Lilly and Company |
207,651 |
0.32% |
Stats |
| 74 (11) |
Velcade
Takeda Pharmaceuticals North America, Inc |
203,741 |
8.04% |
Stats |
| 75 (11) |
Restasis
Allergan, Inc |
202,233 |
7.28% |
Stats |
| 76 (5) |
Pradaxa
Boehringer Ingelheim Pharmaceuticals, Inc |
201,327 |
0.13% |
Stats |
| 77 () |
Varivax
Merck & Co., Inc. |
200,962 |
|
Stats |
| 78 (5) |
fentanyl
Generic |
197,539 |
0.10% |
Stats |
| 79 (1) |
Aciphex
Eisai Corporation |
195,946 |
-3.52% |
Stats |
| 80 (9) |
Prezista
Janssen Pharmaceuticals, Inc |
194,476 |
6.35% |
Stats |
| 81 (18) |
budesonide
Generic |
192,961 |
-24.99% |
Stats |
| 82 (15) |
Orencia
Bristol-Myers Squibb Company |
191,537 |
11.23% |
Stats |
| 83 (5) |
acetaminophen/hydrocodone
Generic |
190,298 |
2.66% |
Stats |
| 84 (8) |
Prevnar 13
Wyeth |
188,578 |
5.30% |
Stats |
| 85 () |
Mirena
Bayer Healthcare Pharmaceuticals |
187,854 |
|
Stats |
| 86 (9) |
VESIcare
Astellas Pharma US |
183,839 |
5.34% |
Stats |
| 87 () |
Gilenya
Novartis Corporation |
182,611 |
|
Stats |
| 88 (10) |
Betaseron
Bayer Healthcare Pharmaceuticals |
181,439 |
5.40% |
Stats |
| 89 (2) |
Lunesta
Sunovion Pharmaceuticals Inc. |
179,192 |
-4.66% |
Stats |
| 90 (10) |
Dexilant
Takeda Pharmaceuticals North America, Inc |
176,733 |
3.24% |
Stats |
| 91 |
Zyvox
Pfizer Inc |
174,134 |
-3.00% |
Stats |
| 92 () |
Evista
Eli Lilly and Company |
172,894 |
|
Stats |
| 93 (1) |
Benicar
Daiichi Sankyo |
172,324 |
-1.31% |
Stats |
| 94 () |
Renvela
Genzyme Corporation |
171,055 |
|
Stats |
| 95 (4) |
Erbitux
Bristol-Myers Squibb Company |
167,914 |
-2.10% |
Stats |
| 96 () |
Xeloda
Roche Pharmaceuticals |
167,560 |
|
Stats |
| 97 () |
Synthroid
Abbott Laboratories |
165,049 |
|
Stats |
| 98 () |
Victoza
Novo Nordisk Inc. |
164,409 |
|
Stats |
| 99 (3) |
Ventolin HFA
GlaxoSmithKline |
160,832 |
-6.88% |
Stats |
| 100 (95) |
Seroquel
AstraZeneca Pharmaceuticals |
159,858 |
-86.23% |
Stats |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
1)
8)
)
